Acambis, sanofi-aventis deal

sanofi-aventis will acquire vaccine company Acambis for 190p per share or about £276 million ($553 million) in cash. The price is a 64% premium to Acambis’ close of 116p on July 25, before the deal was announced. The pharma company will gain Acambis’ ACAM2000 smallpox vaccine, which is approved in the U.S. and for which Acambis recently received a 10-year, $425 million contract from the U.S. Centers for Disease Control and Prevention (CDC) (see BioCentury, April 28). ...